Information For Authors
- Manuscript Submission Guidelines
- Author Benefits Program
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications.
Please read all the instructions to authors before submitting.
Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc. By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal. Upon acceptance of any manuscript, all authors will receive a follow-up email with instructions on how to complete our online Copyright Agreement form.
FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM MAY RESULT IN A DELAY OF PUBLICATION.
The corresponding author is responsible for communicating with coauthors to make sure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.
Click here to submit your paper via our fast and user-friendly electronic submission system.
PREPARATION OF MANUSCRIPT
Submit text manuscript in Microsoft Word double spaced.
On the first page, give the title of the article, name(s) of author(s), institutional affiliation(s), and the name and complete address, phone and fax numbers of the corresponding author. Following this, please include the introduction, materials and methods, results, discussion, acknowledgments, references, tables, and figure legends.
Results and Discussion should be separate sections. Number pages consecutively; the first author's last name should appear on each page. Authors should review the style and clarity of their manuscripts with colleagues before submission. Please follow this protocol to avoid delay in publication. Authors should note that manuscripts may be edited if needed for grammar and usage. Be prepared to enter a running title of no more than 45 characters, as well as an abstract of about 200 words, stating the aims, results, and conclusions drawn from the study.
TABLES AND ILLUSTRATIONS
Number each table consecutively and give each table a title. Each table must be in its own file. Each table must stand alone, i.e., contain all necessary information in the caption, and the table itself must be understood independently of the text. Details of experimental conditions should be included in the table footnotes. Information that appears in the text should not be repeated in tables, and tables should not contain data that can be given in the text in one or two sentences.
A legend should be supplied for each figure, and all legends numbered consecutively and provided (double spaced) in a separate file or as part of the text file. Figures should be numbered in the order cited in the text. Images should not show the name of a manufacturer or reveal patients’ name(s). Please keep in mind that the figures will be reduced, so please do not submit large figures/graphs that contain small type, as the text within the figure will not be readable after reduction. Please follow these guidelines for submitting figures:
- Do NOTembed art files into a Word or PDF document.
- Line illustrations should be submitted at 1200 dpi.
- Halftones and color should be submitted at a minimum of 300 dpi.
- Save as either TIFF or EPS files.
- Color art must be saved as CYMK - not RGB Black and White art must be submitted as grayscale – Do NOT submit PowerPoint, PDF, Bitmap or Excel files.
- Please name your artwork files with the submitting authors name i.e. SmithFig1.tif, SmithTable2.tif etc. Authors who do not follow these guidelines may have their submission returned to them without being reviewed.You will be given directions on how to correct any files which do not pass.< ADDITIONAL INFORMATION ABOUT Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines: All files should be scanned at 100% size.
· 300 dpi
· Final color mode: cmyk
· save file as: .tif or .eps
If you need directions on how to convert a Power Point slide to acceptable format go to https://home.liebertpub.com/MEDIA/pdf/ppconvert.pdf
The Journal will publish color photographs, but the cost must be borne by the author. For further details, contact the Publisher.
If no conflicts exist, the authors must state “No competing financial interests exist."
Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the manuscript, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the manuscript is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.htlm#conflicts for further guidance.
Double space all references. Number each reference consecutively in the manuscript in order of citation. Number references consecutively (not alphabetically) in the reference section. Abbreviations of journal titles should follow MEDLINE. List the names of all authors—do not use et al. Accuracy of citation is the responsibility of the authors; remember that inaccurate references are highly frustrating to the reader, the cited author, and indexing services.
Use the following format:
De Lencastre, H., M. Chung, and H. Westh. 2000. Archaic strains of methicillin-resistant Staphylococcus aureus: molecular and microbiological properties of isolates from the 1960s in Denmark. Microb. Drug Resist. 6:1-10.
Doyle, M.P., L.R. Beuchat, and T.J. Montville. 2001. Food Microbiology Fundamentals and Frontiers. 2nd ed. ASM Press, Washington, DC.
Chapter in a book:
Tomasz, A. 1990. Auxiliary genes assisting in the expression of methicillin resistance in Staphylococcus aureus. In R.P. Skurray and R.A. Novick (ed.), Molecular biology of the staphylococci. VCH Publishers, New York, pp. 565-583.
Scacheri, P., J. Crabtree, A. Kennedy, G. Swain, J. Ward, S. Marx, A. Spiegel, and F. Collins. 2006. V804 RET mutation in MEN2A: first report. J. Int. Med. 255:712 (abstract).
Lavilla, S., J.J. González-López, M.N. Larrosa, R.M. Bartolomé, and G. Prat. 2008. Prevalence of the quinolone-modifying enzyme aac(6´)-Ib-cr in extended-spectrum b-lactamase-producing enterobacterial isolates in Barcelona. Abstract presented at the 18th Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, April 19–22. Abstract no. P1523.
Health Protection Agency (HPA). 2005. Detection of Campylobacter species. National Standard Method F 21, Issue 2. Available at www.hpa-standardmethods.org.uk/pdf_sops.asp.
When dates from an unpublished source are given, supply the researcher's name. If work is in press, give journal in which it is to be published. PERMISSIONS The author must obtain permission to reproduce figures, tables, and text from previously published material. Written permission must be obtained from the original copyright holder (generally the publisher, not the author or editor) of the journal or book concerned. An appropriate credit line should be included in the figure legend or table footnote, and full publication information should be included in the reference list. Written permission must be obtained from the author of any unpublished material cited from other laboratories. All permissions listings must be shown in the manuscript—they cannot be entered on proofs.
Manuscripts submitted to this Journal must not be under consideration elsewhere. Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
STUDY DESIGN AND ETHICS
If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images of patients. The Journal does not provide a generic patient release form.
Any identifying information should not be published in descriptions or photographs unless the information is essential for scientific purposes and the patient (or parent/guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be submitted. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication.]] Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, the manuscript should contain assurances/statements that such changes do not distort scientific meaning.
In keeping with patients’ rights of privacy, the Journal does not require the submission of patient consent forms, but instead requires the author(s) to retain and archive all patient consent documentation. Upon submission of a manuscript for review, the authors must make a statement in a cover letter to the Editor/Journal which attests they have received and archived written patient consent.
ETHICS OF EXPERIMENTATION
All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. (http://ethics.od.nih.gov/.)
Ethical Treatment of Animals
All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles, and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.
Microbial Drug Resistance is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle 10801-5215 Telephone: (914) 740–2100; fax: (914) 740–2101.; E-mail: firstname.lastname@example.org Internet: www.liebertpub.com
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email email@example.com.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email firstname.lastname@example.org or visit Liebert Open Access for more information.